Introduction
============

Brain white matter damage is a relatively common neurological disease. Along with the increasing improvement of medical technologies, the technologies of obstetrics and neonate intensive care have also been improved. Therefore, the survival rate of premature infants has been obviously increased. However, the incidence of brain damage of premature infants is also gradually increasing ([@b1-etm-0-0-7539]). Brain white matter damage is one of the main neuropathological forms of brain damage of premature infants. It can influence their intelligence development and cause sequela of nervous system, such as dysnoesia and cerebral palsy. As a result, heavy burden falls on the family of the children and society in general ([@b2-etm-0-0-7539]). Premature infants suffering from white matter damage do not show specific clinical symptoms or signs at early stage, and it is hard to diagnose the problem simply by clinical manifestations. Besides, no effective intervention measures have been developed yet. Therefore, it is crucial to find an effective treatment or prevention method in order to improve patients\' living quality ([@b3-etm-0-0-7539]). IL-6 has been shown to have neurotrophic and neuroprotective effects as well as neurotoxic effects on the central nervous system ([@b4-etm-0-0-7539]). S100β protein and serum neuron-specific enolase (NSE) are among the well-known markers of brain damage. They can reflect the degree of the brain damage as well as the neurological function damage ([@b5-etm-0-0-7539]). Ganglioside are a kind of essential glycolipids of ganglion series for the nerve growth and brain development and promote nerve regeneration ([@b6-etm-0-0-7539]). In the present study, by giving ganglioside to premature infants suffering from white matter damage, we aimed to show its possible efficacy and to analyze the effect of ganglioside on IL-6, NSE and S100β levels with the expectation to provide a basis for the treatment on premature infants suffering from white matter damage.

Patients and methods
====================

### General data

From February 2016 to March 2017, 76 cases of premature infants suffering from white matter damage were selected using a random sampling method. The inclusion criteria were i) meeting the diagnostic criteria of white matter damage ([@b7-etm-0-0-7539]); ii) premature infants; and iii) informed consent forms signed by parents. Exclusion criteria were i) term infants; and ii) patients allergic to the medicine used in this research. The study was approved by the Ethics Committee of Tianjin Central Hospital of Obstetrics and Gynecology (Tianjin, China) and informed consents were signed by the guardians of the child patients. There were respectively 38 cases in the observation and control group. Comparison of the general data between the children in the two groups showed that they were not significantly different (P\>0.05) ([Table I](#tI-etm-0-0-7539){ref-type="table"}).

### Treatment

Control group was given conventional treatment, which included warmth retention, reasonable oxygen supply and scientific feeding. Good ventilation was maintained for patients and their blood gas and pH values were kept within the normal range. Peripheral region and various organs were kept with enough hemoperfusion, and the heart rate and blood pressure were kept within the normal range. Blood glucose was maintained at normal high value (5.0 mmol/l) to ensure the metabolic needs of neurons. Medical staff closely supervised any change of the disease condition of the children. Occurrence of any abnormality was taken care of by symptomatic treatment. The observation group was given ganglioside (SFDA approval no. H20066833; Changchun Xiangtong Pharmacy, Co., Ltd., Xiangtong, China). The treatment plan was as follows: 20 mg of intravenous drip every day, 14 days as one course and 1--3 courses should be given based on the disease condition of the children.

### Test of relative indexes

GE Voluson 730 Expert ultrasonic testing instrument \[GE Healthcare (China) Co., Ltd., Beijing, China\] was used for craniocerebrum ultrasonic detection at 1, 7 and 14 days after birth (transducer frequency, 5--9 mHz). Coronal and sagittal scans were conducted via bregma. Images at the central part and occipital horn of lateral ventricle were observed. Abnormal echo of white matter was taken as abnormity.

Central venous blood (2 ml) was extracted from children before and after treatment. The supernatant was collected after centrifugation at 3,000 × g for 10 min at 4°C and kept at −70°C. ELISA was used to measure IL-6, NSE and S100β levels. The relative kits were provided by the R&D Systems, Inc. (Richmond, CA, USA) and were used according to the manufacturer\'s instructions. An enzyme-labeling instrument (Jiangsu Potebio Co., Ltd., Jiangsu, China) was used to read OD values (wavelength, 450 nm) and to calculate the concentrations of IL-6, NSE and S100β.

### Evaluation methods

The following degrees were used to evaluate the white matter damage ([@b7-etm-0-0-7539]): i) light: by ultrasonic detection, the echo intensity of white matter around ventricle of the patients was weaker than that of choroid; ii) medium: ultrasonic results showed that the echo intensity of white matter around ventricle was the same as that of the choroid plexus; iii) serious: ultrasonic results showed that the echo intensity of white matter around ventricle was stronger or the same as that of the choroid plexus, but the range exceeded the triangle area of lateral ventricle.

Craniocerebrum ultrasonic detection was used to observe the condition of white matter around the ventricle of the children in the two groups, before and after treatment. ELISA was used to detect the concentration levels of IL-6, NSE and S100β. Gesell developmental scale ([@b8-etm-0-0-7539]) was used to evaluate the developmental quotient (DQ) of various function regions of the children in the two groups at 12 months after treatment ([@b9-etm-0-0-7539]). Function regions include social adaptation, gross motor, fine motor, language, and personal social contact.

### Statistical analysis

SPSS 19.0 (IBM Corp., Armonk, NY, USA) was used for data analysis. Measurement data were expressed as mean ± standard deviation (mean ± SD) and were compared by t-test; enumeration data were expressed as percentage and compared by χ^2^ test. Treatment effect was evaluated by a rank sum test. ANOVA was used for multiple group comparisons with Dunnett\'s post hoc test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

Comparison of the efficacy on child patients in the two groups showed that the total effective rate in the observation group was significantly higher than that in the control group (P\<0.05) ([Table II](#tII-etm-0-0-7539){ref-type="table"}).

Comparison of the gray values of craniocerebrum ultrasonic detection of the children in the two groups showed that there was no obvious change of grey value of craniocerebrum ultrasonic detection in the control group (P\>0.05). The grey value of craniocerebrum ultrasonic detection in the observation group was significantly reduced at 7 and 14 days after birth ([Table III](#tIII-etm-0-0-7539){ref-type="table"}).

Comparison of IL-6 levels of the children in the two groups showed that at 7 and 14 days after birth, the IL-6 levels of both groups were significantly reduced, compared to the 1st day after birth, and the levels of the observation groups were significantly lower than that of the control group (P\<0.05) ([Table IV](#tIV-etm-0-0-7539){ref-type="table"}).

Comparison of NSE levels of the children in the two groups showed that at 7 and 14 days after birth, the NSE levels of both groups were significantly reduced, compared to the 1st day after birth, and the levels of the observation group were significantly lower than those of the control group (P\<0.05) ([Table V](#tV-etm-0-0-7539){ref-type="table"}).

Comparison of S100β levels of children in the two groups showed that at 7 and 14 days after birth, the S100β levels of both groups were significantly reduced, compared to the 1st day after birth, and the levels of the observation group were significantly lower than that of the control group (P\<0.05) ([Table VI](#tVI-etm-0-0-7539){ref-type="table"}).

Comparison of the DQ condition at 12 months after treatment between the children in the two groups showed that the observation group scored significantly higher than the control group in the aspects of social adaptation, gross motor, fine motor, language, and personal social contact (P\<0.05) ([Table VII](#tVII-etm-0-0-7539){ref-type="table"}).

Comparison of the sequel incidence between the children in the two groups showed that the sequel incidence of the observation group was significantly lower than that of the control group (P\<0.05) ([Table VIII](#tVIII-etm-0-0-7539){ref-type="table"}).

Discussion
==========

White matter damage of premature infants is one of the most common causes of cerebral palsy, audiovisual obstacles, intelligence development retardation, epilepsy, learning difficulty and other brain damage syndromes, which seriously influence their quality of life ([@b10-etm-0-0-7539]). Prior studies have shown that there is a close relation between the occurrence of newborn brain damage and the fetal age (especially related to the low cerebrovascular developmental maturity of premature infants) ([@b11-etm-0-0-7539]). White matter damage of premature infants is caused by various factors, such as perinatal hypoxia and ischemia, developmental immaturity of brain structure, insufficient endocrine hormone as a result of getting out of matrix and placenta too early, perinatal infection, inflammatory reaction and deviation of neurodevelopment ([@b12-etm-0-0-7539]). At present, the pathogenesis of white matter damage of premature infants is not fully known. Usually, hypoxia and ischemia are taken as one of the main causes of the disease. The cerebrovascular developmental immaturity of premature infants can cause ischemic injury. In the process of damage, free radical damage, glutamate-induced excitotoxicity, microglia inflammation immunologic reaction and other damage mechanisms occur and finally lead to liquefaction and volume reduction of white matter ([@b13-etm-0-0-7539]).

Even though most treatments are still at exploration stage, the current treatments for the white matter damage of premature infants are the following: medicine intervention (brain active element, neurotrophic factor, erythropoietin, ganglioside and deferoxamine) and neural stem cell transplantation via ventricle ([@b14-etm-0-0-7539]). Results of the present study showed that the total effective rate of the observation group was higher than that of the control group (P\<0.05). This might be due to the ganglioside capability to promote recovery after central nervous system damage. It might also affect the generation of cell transmembrane signal, interact with extracellular information and exert the effect of stabilizing membrane structure and function. Besides, ganglioside can prevent the influx of Ca^2+^, reduce the concentration of free radicals, reduce free radical damage, antagonize excessive activation of glutamate receptor, and reduce the damage to precursor cells of oligodendrocytes ([@b15-etm-0-0-7539]). Moreover, ganglioside can strengthen neurotrophic factors, and promote neuron regeneration.

Craniocerebrum ultrasonic detection has a high clinical diagnostic value and can be used to continuously and dynamically observe the condition of white matter of premature infants. This technique uses a sound wave with short pulse and high frequency and after reflection, refraction dispersion and absorption forms ultrasonic images on the oscilloscope screen. It has the advantages of easy operation and does not require the patient to move, and it is of high clinical diagnostic value ([@b16-etm-0-0-7539]). Results of this research showed that at 7 and 14 days after birth, the gray value of craniocerebrum ultrasonic detection of the control group showed no obvious change (P\>0.05). At 7 and 14 days after birth, the gray value of craniocerebrum ultrasonic detection of the observation group was significantly reduced (P\<0.05). This indicated that after ganglioside treatment, the echo of white matter around ventricle of the children got weaker and the damage degree of the children was well controlled and recovered.

IL-6 is a multi-functional cytokine related to inflammatory regulation and immune reaction, and it can take part in the inflammatory reaction of human body. It is produced by the astrocytes and microglias which are distributed in hippocampus, hypothalamus, cortex and other regions ([@b17-etm-0-0-7539]). Results of the present study showed that at 7 and 14 days after birth, the IL-6 of the children in the two groups were significantly reduced, compared to the 1st day after birth, and the levels in the observation group were significantly lower than that of the control group (P\<0.05). This might be due to the fact that in premature infants suffering from white matter damage, the brain tissue cells keep secreting IL-6 and local inflammatory reaction occurs. In this case, the intracranial pressure is increased and as the treatment time passes the concentration of IL-6 is reduced to levels below normal level, exerting central immune mediation, nerve repair and other physiological effects.

S100β protein is one of the acid calcium-binding proteins in glial cells. At normal condition, S100β can pass renal metabolism but not the blood-cerebrospinal fluid barrier. When brain damage occurs, blood-brain barrier can be destroyed and its permeability can increase. S100β can enter blood circulation by blood-brain barrier. Therefore, the level of S100β can be taken as the indicator to diagnose brain damage ([@b18-etm-0-0-7539]). NSE is a dimer-enzyme, often found in neuron cytoplasm, and when neuron damage occurs, NSE is released to extracellular fluid ([@b19-etm-0-0-7539]). Our results showed that at 7 and 14 days after birth, S100β and NSE levels in both groups were significantly reduced, compared to the 1st day after birth, and the levels of the observation group were significantly lower than that of the control group (P\<0.05). This may be due to the fact that ganglioside can activate the production of membrane lipids, stabilize the structure and function of cell membrane and directly exert a neuroprotective effect in brain, resulting in reduction of the brain damage ([@b20-etm-0-0-7539]).

After 12 months, the total effective rate of the observation group was higher than that of the control group. The observation group scored significantly higher DQ than the control group in the aspects of social adaptation, gross motor, fine motor, language and personal social contact. The sequel of patients in the observation group was significantly lower than that of the control group (P\<0.05). This is because conventional treatment can hardly reverse the brain damage in premature infants. The efficacy is not obvious and tends to leave sequels. While the ganglioside can provide essential neurenergen for the development of the children, so that rich neural network may be developed in their brains, repair and promote the development of brain nerves again. Therefore, the normal intelligence development of the children is secured.

We conclude that the intervention treatment with ganglioside for premature infants suffering from white matter damage is beneficial and provides a protective effect. It also reduces sequel and produces promising results.
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###### 

Comparison of baseline data between the child patients in the two groups.

  Items                                 Control group (n=38)   Observation group (n=38)   t/χ^2^ value   P-value
  ------------------------------------- ---------------------- -------------------------- -------------- ---------
  Child patient sex (male/female)       20/18                  22/16                      0.053          0.818
  Fetal age (weeks)                     29--35                 28--36                                    
  Average fetal age (weeks)             33.18±1.25             33.36±1.36                 0.601          0.550
  Child patient weight (kg)               2.13±0.28              2.12±0.32                0.145          0.885
  Brain white matter damage \[n (%)\]                                                                    
    Light damage                        27 (71.05)             29 (76.32)                 0.068          0.795
    Medium or serious damage            11 (28.95)               9 (23.68)                               

###### 

Comparison of efficacy on child patients in the two groups \[n (%)\].

  Group               n    Obviously effective   Effective     Not effective   Total effective
  ------------------- ---- --------------------- ------------- --------------- -----------------
  Observation group   38   26 (68.42)              7 (18.42)     5 (13.16)     33 (86.84)
  Control group       38   12 (31.58)            11 (28.95)    15 (39.47)      23 (60.53)

The results from the Rank sum test of the efficacy on child patients of the two groups were Z=3.176, P=0.018.

###### 

Comparison of gray values of craniocerebrum ultrasonic detection of child patients in the two groups (mean ± SD).

  Group               n    1 day after birth   7 days after birth                                            14 days after birth
  ------------------- ---- ------------------- ------------------------------------------------------------- ------------------------------------------------------------
  Observation group   38   126.67±3.23           105.35±3.28^[a](#tfn2-etm-0-0-7539){ref-type="table-fn"}^     96.68±3.24^[a](#tfn2-etm-0-0-7539){ref-type="table-fn"}^
  Control group       38   126.27±3.64         125.47±3.36                                                   125.83±3.78
  t value                  0.507               26.414                                                        36.093
  P-value                  0.614               \<0.001                                                       \<0.001

P\<0.05, compared to the 1st day after birth. SD, standard deviation.

###### 

Comparison of IL-6 levels of child patients in the two groups (pg/ml, mean ± SD).

  Group               n    1 day after birth   7 days after birth                                         14 days after birth
  ------------------- ---- ------------------- ---------------------------------------------------------- ----------------------------------------------------------
  Observation group   38   26.63±3.23          20.35±3.28^[a](#tfn3-etm-0-0-7539){ref-type="table-fn"}^   18.38±3.24^[a](#tfn3-etm-0-0-7539){ref-type="table-fn"}^
  Control group       38   26.58±3.64          23.47±3.36^[a](#tfn3-etm-0-0-7539){ref-type="table-fn"}^   21.83±3.78^[a](#tfn3-etm-0-0-7539){ref-type="table-fn"}^
  t value                  0.063                 4.096                                                      4.272
  P-value                  0.950               \<0.001                                                    \<0.001

P\<0.05, compared to the 1st day after birth. SD, standard deviation.

###### 

Comparison of NSE levels of child patients in the two groups (ng/ml, mean ± SD).

  Group               n    1 day after birth   7 days after birth                                        14 days after birth
  ------------------- ---- ------------------- --------------------------------------------------------- ---------------------------------------------------------
  Observation group   38   6.62±1.18           4.64±0.78^[a](#tfn4-etm-0-0-7539){ref-type="table-fn"}^   3.52±0.47^[a](#tfn4-etm-0-0-7539){ref-type="table-fn"}^
  Control group       38   6.65±1.13           5.32±0.61^[a](#tfn4-etm-0-0-7539){ref-type="table-fn"}^   5.03±0.34^[a](#tfn4-etm-0-0-7539){ref-type="table-fn"}^
  t value                  0.113                 4.233                                                   16.046
  P-value                  0.910               \<0.001                                                   \<0.001

P\<0.05, compared to the 1st day after birth. NSE, neuron-specific enolase; SD, standard deviation.

###### 

Comparison of S100β levels of child patients in the two groups (ng/ml, mean ± SD).

  Group               n    1 day after birth   7 days after birth                                          14 days after birth
  ------------------- ---- ------------------- ----------------------------------------------------------- ------------------------------------------------------------
  Observation group   38   132.89±3.23         115.52±3.15^[a](#tfn5-etm-0-0-7539){ref-type="table-fn"}^     94.83±3.04^[a](#tfn5-etm-0-0-7539){ref-type="table-fn"}^
  Control group       38   132.36±3.28         123.74±3.47^[a](#tfn5-etm-0-0-7539){ref-type="table-fn"}^   117.79±3.15^[a](#tfn5-etm-0-0-7539){ref-type="table-fn"}^
  t value                  0.710               10.812                                                      32.331
  P-value                  0.480               \<0.001                                                     \<0.001

P\<0.05, compared to the 1st day after birth. SD, standard deviation.

###### 

Comparison of the DQ condition between child patients in the two groups (mean ± SD).

  Group               n    Social adaptation   Gross motor   Fine motor   Language     Personal social contact
  ------------------- ---- ------------------- ------------- ------------ ------------ -------------------------
  Observation group   38   86.73±5.05          85.43±5.63    77.23±3.56   86.58±3.57   86.58±3.57
  Control group       38   72.24±5.37          71.86±5.78    59.56±3.47   70.56±3.48   69.56±3.48
  t value                  12.117              10.367        21.911       19.808       21.045
  P-value                  \<0.001             \<0.001       \<0.001      \<0.001      \<0.001

DQ, developmental quotient; SD, standard deviation.

###### 

Comparison of sequel incidence between child patients in the two groups \[n (%)\].

  Group               n    Cognitive disturbance   Cerebral palsy   Intelligence development retardation   Mental retardation   Total
  ------------------- ---- ----------------------- ---------------- -------------------------------------- -------------------- -------------
  Observation group   38   2 (5.26)                1 (2.63)         1 (2.63)                               1 (2.63)               5 (13.16)
  Control group       38   5 (13.16)               4 (10.53)        4 (10.53)                              5 (13.16)            18 (47.37)
  χ^2^ value                                                                                                                    0.325
  P-value                                                                                                                       0.003
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